Prevalence of drug-resistant tuberculosis in Iran: Systematic review and meta-analysis

The spread of multidrug-resistant tuberculosis (MDR-TB) is a major public health problem worldwide. Although drug resistance is common in some countries and rare in others, the extent of this condition is not precisely known in Iran. We searched several databases including PubMed, Web of Science, Sc...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:American journal of infection control Ročník 42; číslo 11; s. 1212 - 1218
Hlavní autoři: Nasiri, Mohammad Javad, Dabiri, Hossein, Darban-Sarokhalil, Davood, Rezadehbashi, Maryam, Zamani, Samin
Médium: Journal Article
Jazyk:angličtina
Vydáno: New York, NY Elsevier Inc 01.11.2014
Elsevier
Mosby-Year Book, Inc
Témata:
Antitubercular Agents - pharmacology
Bacterial diseases
Biological and medical sciences
Drug resistance
Epidemiology. Vaccinations
General aspects
Human bacterial diseases
Humans
Infectious Disease
Infectious diseases
Iran
Iran - epidemiology
Isoniazid - pharmacology
Medical sciences
Meta-analysis
Multidrug resistant organisms
Prevalence
Public health
Streptomycin - pharmacology
Systematic review
Tuberculosis
Tuberculosis and atypical mycobacterial infections
Tuberculosis, Multidrug-Resistant - epidemiology
Iran
Asia
Iran
Drug resistance
Tuberculosis
Infection
Prevention
Treatment resistance
Prevalence
Bacteriosis
Check
Mycobacterial infection
Epidemiology
Bibliographic review
ISSN:0196-6553, 1527-3296, 1527-3296
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The spread of multidrug-resistant tuberculosis (MDR-TB) is a major public health problem worldwide. Although drug resistance is common in some countries and rare in others, the extent of this condition is not precisely known in Iran. We searched several databases including PubMed, Web of Science, Scopus, Iran Medex, and Scientific Information Database to identify studies addressing drug-resistant tuberculosis in Iran. A total of 19 reports published from different regions of Iran from March 1999-May 2013 were included in this study. The meta-analyses revealed that 23% (95% confidence interval [CI], 21.8-24.2) of new cases and 65.6% (95% CI, 62.5-68.5) of previously treated cases were resistant to at least 1 drug. Furthermore, MDR-TB was found in 5.1% (95% CI, 4.4-5.8) of new cases, whereas it was found in 33.7% (95% CI, 30.8-36.7) of retreatment cases. The highest rate of resistance in new and previously treated cases was seen against streptomycin (19%) and isoniazid (47%), respectively. The results of the present study underscore the need for further enforcement of TB control strategies. Drug susceptibility testing, establishing advanced diagnostic facilities, and continuous monitoring of drug resistance are recommended for prevention and control of MDR-TB.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ObjectType-Undefined-4
ISSN:0196-6553
1527-3296
1527-3296
DOI:10.1016/j.ajic.2014.07.017